Chardan Capital Markets downgraded Regulus Therapeutics (NASDAQ: RGLS) from Buy to Neutral with a price target of $1.00 (from $2.50).Analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE